Integral Health Asset Management LLC Acquires 250,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Integral Health Asset Management LLC boosted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 33.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,000,000 shares of the biopharmaceutical company’s stock after buying an additional 250,000 shares during the quarter. Cytokinetics makes up approximately 4.0% of Integral Health Asset Management LLC’s holdings, making the stock its 5th largest holding. Integral Health Asset Management LLC’s holdings in Cytokinetics were worth $47,040,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp boosted its stake in shares of Cytokinetics by 189.8% in the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 374 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Cytokinetics in the fourth quarter worth about $29,000. AlphaQuest LLC boosted its stake in shares of Cytokinetics by 113,500.0% in the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,135 shares during the last quarter. J.Safra Asset Management Corp boosted its stake in shares of Cytokinetics by 62.1% in the fourth quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 671 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Cytokinetics by 85.8% in the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 842 shares during the last quarter.

Insider Buying and Selling at Cytokinetics

In other news, EVP Andrew Callos sold 3,341 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the transaction, the executive vice president now owns 64,434 shares of the company’s stock, valued at approximately $2,788,059.18. This trade represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Fady Ibraham Malik sold 2,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total transaction of $91,960.00. Following the transaction, the executive vice president now directly owns 116,071 shares in the company, valued at $5,336,944.58. The trade was a 1.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 95,362 shares of company stock valued at $3,899,118 in the last ninety days. Insiders own 2.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on CYTK shares. Barclays lowered their price target on Cytokinetics from $55.00 to $53.00 and set an “overweight” rating on the stock in a research report on Thursday. UBS Group lowered their price target on Cytokinetics from $47.00 to $41.00 and set a “neutral” rating on the stock in a research report on Friday, May 2nd. Evercore ISI upgraded Cytokinetics to a “strong-buy” rating in a research report on Friday, February 7th. Needham & Company LLC reiterated a “buy” rating and set a $72.00 price target on shares of Cytokinetics in a research report on Friday, May 2nd. Finally, Royal Bank of Canada lowered their price target on Cytokinetics from $82.00 to $80.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Cytokinetics has a consensus rating of “Moderate Buy” and an average price target of $74.44.

Cytokinetics Trading Down 2.4%

CYTK stock opened at $31.69 on Monday. The company has a market cap of $3.78 billion, a price-to-earnings ratio of -5.89 and a beta of 0.81. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. The business has a fifty day simple moving average of $40.18 and a 200-day simple moving average of $45.92. Cytokinetics, Incorporated has a 52 week low of $31.67 and a 52 week high of $63.46.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.05. The company had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.77 million. During the same quarter in the prior year, the company posted ($1.33) earnings per share. The firm’s revenue for the quarter was up 89.1% on a year-over-year basis. On average, equities research analysts expect that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.